Effect of Serum Fibrinogen, Total Stent Length, and Type of Acute Coronary Syndrome on 6-Month Major Adverse Cardiovascular Events and Bleeding After Percutaneous Coronary Intervention

This study evaluated the relation between baseline fibrinogen and 6-month major adverse cardiovascular events (MACE) and bleeding after percutaneous coronary intervention (PCI). Three hundred eighty-seven subjects (65.6 ± 16.1 years, 69.5% men, 26.9% acute coronary syndrome [ACS]) who underwent PCI...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2016-05, Vol.117 (10), p.1575-1581
Main Authors: Mahmud, Ehtisham, MD, Ramsis, Mattheus, BS, Behnamfar, Omid, MD, Enright, Kelly, MS, Huynh, Andrew, BS, Kaushal, Khushboo, MD, Palakodeti, Samhita, Li, Shiqian, BS, Teh, Phildrich, MS, Lin, Felice, MD, Reeves, Ryan, MD, Patel, Mitul, MD, Ang, Lawrence, MD
Format: Article
Language:English
Subjects:
Acute Coronary Syndrome - blood
Acute Coronary Syndrome - surgery
Acute coronary syndromes
Aged
Angina pectoris
California - epidemiology
Cardiovascular
Female
Fibrinogen - metabolism
Fibrinolytic Agents - adverse effects
Follow-Up Studies
Heart attacks
Humans
Incidence
Male
Myocardial Infarction - blood
Myocardial Infarction - drug therapy
Myocardial Infarction - epidemiology
Odds Ratio
Percutaneous Coronary Intervention
Postoperative Hemorrhage - blood
Postoperative Hemorrhage - epidemiology
Prognosis
Prosthesis Design
Retrospective Studies
Stents
Survival Rate - trends
Thrombolytic Therapy - adverse effects
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study evaluated the relation between baseline fibrinogen and 6-month major adverse cardiovascular events (MACE) and bleeding after percutaneous coronary intervention (PCI). Three hundred eighty-seven subjects (65.6 ± 16.1 years, 69.5% men, 26.9% acute coronary syndrome [ACS]) who underwent PCI with baseline fibrinogen and platelet reactivity (VerifyNow P2Y12 assay, Accumetrics, San Diego, California) measured were enrolled. Fibrinogen (368.8 ± 144.1 vs 316.8 ± 114.3 mg/dl; p = 0.001), total stent length (TSL; 44.5 ± 25.0 vs 32.2 ± 20.1 mm; p
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2016.02.032